Navigation Links
FDA Warning for N-9 - an Opportunity for VivaGel(R)
Date:12/21/2007

MELBOURNE, Australia, Dec. 21 /PRNewswire-FirstCall/ -- Starpharma Holdings Limited (ASX:SPL, OTC: SPHRY), developer of VivaGel(R) vaginal microbicide today welcomed a decision by the US FDA this week requiring makers of products containing nonoxynol 9 (N9) to carry a warning that the products do not protect against sexually transmitted diseases, including HIV/AIDS and that the use of N-9 products is associated with an increased risk of HIV.

Starpharma's VivaGel(R) is a vaginal gel, being developed to protect women from HIV and HSV-2 (genital herpes) during sex. VivaGel(R) does not use N9. VivaGel(R) is currently in mid-stage clinical trials in the US and Kenya to add to its portfolio of safety data before embarking on population-based efficacy testing.

In the December 18 FDA release they noted:

"FDA is issuing this final rule to correct misconceptions that the chemical N9 in these widely available stand-alone contraceptive products protects against sexually transmitted diseases, including HIV infection," said Janet Woodcock, M.D., FDA's deputy commissioner for scientific and medical programs, chief medical officer, and acting director of the Center for Drug Evaluation and Research (CDER).

"Clinical research has shown that N9 provides no protection against sexually transmitted diseases to the woman if her sexual partner is infected with an STD pathogen or HIV."

In addition, FDA is requiring that the labels warn consumers that the chemical N9 in stand-alone vaginal contraceptives and spermicides can irritate the vagina and rectum, which may increase the risk of contracting HIV/AIDS from an infected partner.

"Starpharma welcomes this clear statement from the FDA," commented Jackie Fairley, Starpharma's CEO. "We feel that this emphasizes the urgent need for products such as VivaGel(R) to assist individuals protect themselves from infection with these serious diseases. Starpharma is intent on developing VivaGel(R), both a
'/>"/>

SOURCE Starpharma
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Campaign for Americas Future Memorandum: Katrina Storm Warning
2. Jump in Youth Suicide Prompts National Childrens Charity KidsPeace to Issue Tips on Prevention, Warning Signs
3. Mayo Clinic study finds FDA warning against antinausea drug droperidol unnecessary
4. Common Early-Warning Symptoms of Ovarian Cancer Identified in CDC/Thomson Healthcare Study
5. Defib Wire Warning Shouldnt Worry Most Users: Experts
6. India, UK Join Growing List of Countries to Require Pictorial Tobacco Warnings
7. Thoratecs ITC Division Receives FDA Warning Letter
8. FDA Issues New Warnings for Anemia Drugs
9. Warning for women who binge drink
10. Avandia Label to Get Heart-Attack Warning
11. FDA Mulls Tougher Warning Label on Kids Flu Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2014)... Pwnie Express today announced the release ... Plug, the R3, an inconspicuous pentesting device whose drop ... remote locations at a fraction of the cost of ... the only company to assess wired and wireless network ... a next-generation penetration testing device in a portable, shippable, ...
(Date:9/3/2014)... 03, 2014 Morris Psychological ... free screenings for depression on October 9, 2014 ... Court). More than 1,000 organizations nationwide will be ... colleges and military installations. After completing a screening, ... and agencies that can offer further evaluation and ...
(Date:9/2/2014)... 03, 2014 Autumn is well ... to celebrate the new season with worldwide people. ... and announced that Hostgator ( http://secure.hostgator.com/~affiliat/cgi-bin/affiliates/clickthru.cgi?id=seohosts ), Arvixe, ... of 2014. , Since 2002 HostGator has ... and the company’s reputation for reliability remains with ...
(Date:9/2/2014)... Fla. (PRWEB) September 02, 2014 ... join together in Tampa Bay from September 4-6 ... annual Scientific Symposium and FARA Energy Ball Gala. ... USF Ataxia Research Center in their pursuit of ... affected by the progressive neuromuscular disease Friedreich’s ataxia ...
(Date:9/2/2014)... 03, 2014 UWDress.com, an experienced supplier ... added a lot of fashionable bridesmaid dresses ... company has launched a special offer to celebrate the ... from 20 to 60 percent off. , The ... announce our new fashionable bridesmaid dresses for consumers from ...
Breaking Medicine News(10 mins):Health News:Pwnie Express Releases Next Generation Penetration Testing Device: The Pwn Plug R3 2Health News:Pwnie Express Releases Next Generation Penetration Testing Device: The Pwn Plug R3 3Health News:Pwnie Express Releases Next Generation Penetration Testing Device: The Pwn Plug R3 4Health News:Screenings for Depression by Morris Psychological Group, October 9, 2014 from 4:30 to 8:30pm, Rockaway Townsquare Mall (Macy’s Court) 2Health News:Top10BestSEOHosting.com Celebrates The Coming Of Autumn And Release Reseller Hosting Suppliers Of 2014 2Health News:Event Gathers World-Renowned Researchers and Community Leaders to Find a Cure for Rare Disease, Friedreich’s Ataxia 2Health News:Event Gathers World-Renowned Researchers and Community Leaders to Find a Cure for Rare Disease, Friedreich’s Ataxia 3Health News:Elegant Bridesmaid Dresses For 2014, Latest Designs From UWDress.com 2
... DENVER, July 28 ThinIdentity Corporation, a ... announced that Alegent Health is moving forward with plans ... The first installation is located at its Mercy Hospital ... has over 1,000 caregivers using the ThinIdentity solution to ...
... , WILMINGTON, Delaware, July 28 ... - 2014), published by,MarketsandMarkets ( http://www.marketsandmarkets.com ), the total drug-device,combination ... out of,which the U.S. market will account for nearly 30.9% ... a CAGR of 11.8% from 2009 to 2014. , ...
... ... CompactRIO embedded real-time platform at the 15th annual NIWeek, opening Aug. 4 at the ... and exhibition hosted by National Instruments. , ... Irvine, CA (PRWEB) July 27, 2009 -- MoviMED ( www.movimed.com ...
... ... find medical assistant training at All Allied Health Schools. , ... Seattle, Wash. (PRWEB) July 28, 2009 -- With current unemployment ... In 2006, the Bureau of Labor Statistics predicted 35 percent growth in medical assistant ...
... ... centers and healthcare facilities acquire financing for new and professionally refurbished medical equipment. , ... (Vocus) July 28, 2009 -- With ... to purchase medical equipment . DRE, Inc. — named a Company of the Year ...
... , ... Cleanroom wipers manufactured by Teknipure offer innovative ... to finish in one facility enabling maximum quality control and are ... Basis Weight, Sorbency, Liquid Particle Count, Non-Volatile Residue levels, Ionic Extractable ...
Cached Medicine News:Health News:Alegent Health Turns to ThinIdentity(TM) to Improve Caregiver Productivity 2Health News:Alegent Health Turns to ThinIdentity(TM) to Improve Caregiver Productivity 3Health News:Drug-Device Combination Market Worth US$18.54 Billion by 2014 2Health News:Drug-Device Combination Market Worth US$18.54 Billion by 2014 3Health News:MoviMED Announces Participation in NIWeek 2009 Conference to Examine Trends and Technologies for Boosting Productivity and Increasing Competitive Advantage 2Health News:MoviMED Announces Participation in NIWeek 2009 Conference to Examine Trends and Technologies for Boosting Productivity and Increasing Competitive Advantage 3Health News:Students Connect with Stable Careers Through Updated Medical Assistant Career Resources on All Allied Health Schools 2Health News:Students Connect with Stable Careers Through Updated Medical Assistant Career Resources on All Allied Health Schools 3Health News:Financing Available for Healthcare Equipment from DRE Medical Equipment 2Health News:Financing Available for Healthcare Equipment from DRE Medical Equipment 3Health News:Teknipure Cleanroom Wipers Offer Innovative Solutions for Contamination Control Engineers 2
(Date:9/2/2014)... 2014 Perrigo Company plc, a public limited company ... (the " Company "), today announced that it is offering ... new 1.30% Senior Notes due 2016 (the " 2016 Exchange ... 2018 (the " 2018 Exchange Notes "), $800,000,000 of its ... Notes ") and $400,00,000 of its new 5.30% Senior Notes ...
(Date:9/2/2014)... AUSTIN, Texas , Sept. 2, 2014 /PRNewswire/ ... Phase III study being conducted in the US ... a True Human™ monoclonal antibody therapy, is being ... is further complicated with cachexia. The primary endpoint ... in Xilonix treated patients to a control population ...
(Date:9/2/2014)... NEW YORK , Sept. 2, 2014 /PRNewswire/ ... report is available in its catalogue: ... 2014 http://www.reportlinker.com/p0689743/Acute-Heart-Failure-Global-Clinical-Trials-Review-H2-2014.html ... H2, 2014 Summary GlobalData,s clinical ... Review, H2, 2014" provides data on the Acute ...
Breaking Medicine Technology:Perrigo Company plc Announces Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023 and 5.30% Senior Notes Due 2043 2Perrigo Company plc Announces Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023 and 5.30% Senior Notes Due 2043 3Perrigo Company plc Announces Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023 and 5.30% Senior Notes Due 2043 4XBiotech Halts Study, Reports Positive Phase III Results with Antibody Therapy for Cancer 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 4Acute Heart Failure Global Clinical Trials Review, H2, 2014 5Acute Heart Failure Global Clinical Trials Review, H2, 2014 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 7Acute Heart Failure Global Clinical Trials Review, H2, 2014 8
... Work Status and,Productivity, WASHINGTON, May 23, 2007 /PRNewswire-FirstCall/ ... (DDW), from,long-term extensions of the ACT trials (Active ... moderately to severely active,ulcerative colitis (UC) who had ... the trials maintained,improvement in their clinical symptoms for ...
... WIRE)--May 23, 2007 - Synta,Pharmaceuticals Corp., (NASDAQ: ... and commercializing small,molecule drugs to treat severe ... data from the Phase 2b clinical,trial in ... drug,candidate, STA-4783, will be presented at the ...
Cached Medicine Technology:Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 2Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 3Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 4Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 5Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 6Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 7Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 8Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 9Synta Oncology Candidate STA-4783 Clinical Trial Results to Be,Presented at the ASCO Annual Meeting 2Synta Oncology Candidate STA-4783 Clinical Trial Results to Be,Presented at the ASCO Annual Meeting 3
... Metrikas pager-sized A1cNow ... technology to provide healthcare ... access to quantitative A1C ... indicator of diabetes management ...
... Vein Treatment. It is estimated that 25% of ... veins. In the United States, more than half ... from painful and unsightly venous disease., The VenaCure ... vascular therapy for the treatment of varicose veins. ...
Inquire...
Inquire...
Medicine Products: